METACRINE : UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN - Form 8-K

METACRINE UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN


- U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitis


... | February 11, 2022

Related Keywords

Preston Klassen ,Exchange Commission ,Drug Administration ,Metacrine Inc ,Nasdaq ,Private Securities Litigation Reform Act ,Quarterly Report ,Metacrine ,Nc Stock Exchange ,News ,Information ,Press Release ,Updates ,Bd ,Linical ,Development ,Strategy ,End ,Implements ,Restructuring ,Fda ,Clears ,O ,Valuate ,Et642 ,Or ,The ,Treatment ,F ,Lcerative Mtcr Us59101e1038 ,